Abstract:AbstractPurposeTo explore the relevance of cytogenetic or molecular genetic abnormalities to clinical variables, including clinical and laboratory characteristics and prognosis in Chinese patients with myelodysplastic syndromes (MDS).MethodsA total of 634 consecutive patients diagnosed with MDS at The First Affiliated Hospital, Zhejiang University School of Medicine from June 2008 to May 2018 were retrospectively included in this study. All patients had evaluable cytogenetic analysis, and 425 patients had MDS‐related mutations sequencing.Results38.6% of patients displayed abnormal karyotypes. The most common cytogenetic abnormality was +8 (31%). Sole +8 was related to female (p = 0.002), hemoglobin >10 g/dL (p = 0.03), and <60 years old (p = 0.046). TP53 mutations were associated with complex karyotype (CK) (p < 0.001). DNMT3A mutations correlated with ‐Y (p = 0.01) whereas NRAS mutations correlated with 20q‐ (p = 0.04). The overall survival (OS) was significantly inferior in patients with +8 compared with those with normal karyotype (NK) (p = 0.003). However, the OS of sole +8 and +8 with one additional karyotypic abnormality was not different from NK (p = 0.16), but +8 with two or more abnormalities had a significantly shorter OS than +8 and +8 with one additional karyotypic abnormality (p = 0.02). In multivariable analysis, ≥60 years old, marrow blasts ≥5% and TP53 mutations were independent predictors for poor OS (p < 0.05), whereas SF3B1 mutations indicated better prognosis. Male IDH1 and IDH2 mutations and marrow blasts ≥5% were independent risk factors for worse leukemia free survival (LFS) (p < 0.05).ConclusionIn this population of Chinese patients, trisomy 8 is the most common karyotypic abnormality. Patients with +8 showed a poorer OS compared with patients with NK. Sole +8 and +8 with one additional karyotypic abnormality had similar OS with NK, whereas +8 with two or more abnormalities had a significantly shorter OS. DNMT3A mutations correlated with ‐Y and NRAS mutations correlated with 20q‐. TP53 mutations were associated with CK and had a poor OS. SF3B1 mutations indicated a favorable OS. IDH1 and IDH2 mutations independently indicated inferior LFS.

Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia

Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency

Isocitrate Dehydrogenase 2 Mutations Correlate with Leukemic Transformation and Are Predicted by 2-Hydroxyglutarate in Myelodysplastic Syndromes

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

Impaired DNA damage response and inflammatory signalling underpins hematopoietic stem cell defects in Gata2 haploinsufficiency

1008 – FROM GATA2 HUMAN GENETICS TO LEUKEMIA PREDISPOSITION-GENERATING NETWORKS

Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency

Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance

Hematological phenotypes in GATA2 deficiency syndrome arise from secondary injuries and maladaptation to proliferation

GATA2 heterozygosity causes an epigenetic feedback mechanism resulting in myeloid and erythroid dysplasia

GATA-2 L359V Mutation is Exclusively Associated with CML Progression but Not Other Hematological Malignancies and GATA-2 P250A is a Novel Single Nucleotide Polymorphism.

Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis

Gata-2 Controls Proliferation of Megakaryocyte Progenitors and Its Expression Contributes to Human Ds-Amkl

Gain-Of-Function Mutation of Gata-2 in Acute Myeloid Transformation of Chronic Myeloid Leukemia

The different faces of GATA2 deficiency: implications for therapy and surveillance

Gata2 -L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model

Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience

GATA2 Deficiency in a Patient with a Somatic Mutation of GATA2.

Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

New Progress in the Study of Germline Susceptibility Genes of Myeloid Neoplasms